Medexus Pharmaceuticals (MDP) Competitors

C$3.90 +0.02 (+0.52%)

As of 04:00 PM Eastern

MDP vs. CPH, SUGR, ACB, OGI, and FIRE

Should you be buying Medexus Pharmaceuticals stock or one of its competitors? The main competitors of Medexus Pharmaceuticals include Cipher Pharmaceuticals (CPH), SugarBud Craft Growers (SUGR), Aurora Cannabis (ACB), Organigram (OGI), and Supreme Cannabis (FIRE). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Cipher Pharmaceuticals (TSE:CPH) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cipher Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Medexus Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
4.00
: Cipher Pharmaceuticals has a net margin of 54.37% compared to Medexus Pharmaceuticals' net margin of -0.27%. Cipher Pharmaceuticals' return on equity of 24.23% beat Medexus Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Cipher Pharmaceuticals 54.37% 24.23% 7.90%
Medexus Pharmaceuticals -0.27% -0.52% 4.89%
: Cipher Pharmaceuticals has higher earnings, but lower revenue than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cipher Pharmaceuticals C$50.45M 9.07 C$11.41M C$1.05 17.25
Medexus Pharmaceuticals C$99.43M 1.27 C$3.26M -C$0.02 N/A
: 2.3% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 3.0% of Medexus Pharmaceuticals shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by insiders. Comparatively, 9.1% of Medexus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 2 mentions for Cipher Pharmaceuticals and 1 mentions for Medexus Pharmaceuticals. Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cipher Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Medexus Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Cipher Pharmaceuticals has a beta of 0.725282, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Medexus Pharmaceuticals has a beta of 0.5717, indicating that its stock price is 43% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	54.37%	24.23%	7.90%
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.45M	9.07	C$11.41M	C$1.05	17.25
Medexus Pharmaceuticals	C$99.43M	1.27	C$3.26M	-C$0.02	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cipher Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medexus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cipher Pharmaceuticals beats Medexus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to SugarBud Craft Growers?

SugarBud Craft Growers (CVE:SUGR) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

: SugarBud Craft Growers has a beta of 2.768948, indicating that its stock price is 177% more volatile than the S&P 500. Comparatively, Medexus Pharmaceuticals has a beta of 0.5717, indicating that its stock price is 43% less volatile than the S&P 500.
: SugarBud Craft Growers has a net margin of 2.11% compared to Medexus Pharmaceuticals' net margin of -0.27%. SugarBud Craft Growers' return on equity of 10.07% beat Medexus Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
SugarBud Craft Growers 2.11% 10.07% 5.13%
Medexus Pharmaceuticals -0.27% -0.52% 4.89%
: In the previous week, Medexus Pharmaceuticals had 1 more articles in the media than SugarBud Craft Growers. MarketBeat recorded 1 mentions for Medexus Pharmaceuticals and 0 mentions for SugarBud Craft Growers. SugarBud Craft Growers' average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
SugarBud Craft Growers Neutral
Medexus Pharmaceuticals Neutral
: 0.4% of SugarBud Craft Growers shares are owned by institutional investors. Comparatively, 3.0% of Medexus Pharmaceuticals shares are owned by institutional investors. 30.2% of SugarBud Craft Growers shares are owned by insiders. Comparatively, 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SugarBud Craft Growers
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Medexus Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
4.00
: SugarBud Craft Growers has higher revenue and earnings than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SugarBud Craft Growers C$668.94M 0.41 C$12.12M C$1.68 6.83
Medexus Pharmaceuticals C$99.43M 1.27 C$3.26M -C$0.02 N/A

Company	Net Margins	Return on Equity	Return on Assets
SugarBud Craft Growers	2.11%	10.07%	5.13%
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%

Company	Overall Sentiment
SugarBud Craft Growers	Neutral
Medexus Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SugarBud Craft Growers	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SugarBud Craft Growers	C$668.94M	0.41	C$12.12M	C$1.68	6.83
Medexus Pharmaceuticals	C$99.43M	1.27	C$3.26M	-C$0.02	N/A

Summary

SugarBud Craft Growers beats Medexus Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Aurora Cannabis (TSE:ACB) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

: Medexus Pharmaceuticals has lower revenue, but higher earnings than Aurora Cannabis. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aurora Cannabis C$373.12M 0.74 -C$44.16M -C$1.50 N/A
Medexus Pharmaceuticals C$99.43M 1.27 C$3.26M -C$0.02 N/A
: 4.2% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 3.0% of Medexus Pharmaceuticals shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: Aurora Cannabis presently has a consensus price target of C$9.25, suggesting a potential upside of 96.81%. Given Aurora Cannabis' higher probable upside, equities research analysts plainly believe Aurora Cannabis is more favorable than Medexus Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
3.00
Medexus Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
4.00
: Medexus Pharmaceuticals has a net margin of -0.27% compared to Aurora Cannabis' net margin of -1.69%. Medexus Pharmaceuticals' return on equity of -0.52% beat Aurora Cannabis' return on equity.
Company Net Margins Return on Equity Return on Assets
Aurora Cannabis -1.69% -1.15% -1.87%
Medexus Pharmaceuticals -0.27% -0.52% 4.89%
: In the previous week, Aurora Cannabis and Aurora Cannabis both had 1 articles in the media. Aurora Cannabis' average media sentiment score of 0.90 beat Medexus Pharmaceuticals' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medexus Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Aurora Cannabis has a beta of 0.40301, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Medexus Pharmaceuticals has a beta of 0.5717, indicating that its stock price is 43% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	C$373.12M	0.74	-C$44.16M	-C$1.50	N/A
Medexus Pharmaceuticals	C$99.43M	1.27	C$3.26M	-C$0.02	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-1.69%	-1.15%	-1.87%
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurora Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medexus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Medexus Pharmaceuticals beats Aurora Cannabis on 10 of the 16 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Organigram?

Medexus Pharmaceuticals (TSE:MDP) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

: Medexus Pharmaceuticals has higher earnings, but lower revenue than Organigram. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medexus Pharmaceuticals C$99.43M 1.27 C$3.26M -C$0.02 N/A
Organigram C$279.99M 0.95 -C$57.23M C$0.15 12.27
: 3.0% of Medexus Pharmaceuticals shares are held by institutional investors. Comparatively, 4.0% of Organigram shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by company insiders. Comparatively, 31.3% of Organigram shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Organigram has a consensus target price of C$3.13, suggesting a potential upside of 65.34%. Given Organigram's higher probable upside, analysts plainly believe Organigram is more favorable than Medexus Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medexus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
4.00
Organigram
0 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
3.00
: Organigram has a net margin of 6.49% compared to Medexus Pharmaceuticals' net margin of -0.27%. Organigram's return on equity of 4.86% beat Medexus Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Medexus Pharmaceuticals -0.27% -0.52% 4.89%
Organigram 6.49% 4.86% -5.56%
: In the previous week, Medexus Pharmaceuticals had 1 more articles in the media than Organigram. MarketBeat recorded 1 mentions for Medexus Pharmaceuticals and 0 mentions for Organigram. Medexus Pharmaceuticals' average media sentiment score of 0.00 equaled Organigram'saverage media sentiment score.
Company Overall Sentiment
Medexus Pharmaceuticals Neutral
Organigram Neutral
: Medexus Pharmaceuticals has a beta of 0.5717, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Organigram has a beta of 1.535528, indicating that its share price is 54% more volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$99.43M	1.27	C$3.26M	-C$0.02	N/A
Organigram	C$279.99M	0.95	-C$57.23M	C$0.15	12.27

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%
Organigram	6.49%	4.86%	-5.56%

Company	Overall Sentiment
Medexus Pharmaceuticals	Neutral
Organigram	Neutral

Summary

Organigram beats Medexus Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Supreme Cannabis?

Medexus Pharmaceuticals (TSE:MDP) and Supreme Cannabis (TSE:FIRE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

: Medexus Pharmaceuticals has higher revenue and earnings than Supreme Cannabis. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Supreme Cannabis, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medexus Pharmaceuticals C$99.43M 1.27 C$3.26M -C$0.02 N/A
Supreme Cannabis C$53.29M 0.00 -C$23.65M -C$0.03 N/A
: 3.0% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Given Supreme Cannabis' higher probable upside, analysts plainly believe Supreme Cannabis is more favorable than Medexus Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medexus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
4.00
Supreme Cannabis
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Supreme Cannabis has a net margin of 0.00% compared to Medexus Pharmaceuticals' net margin of -0.27%. Supreme Cannabis' return on equity of 0.00% beat Medexus Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Medexus Pharmaceuticals -0.27% -0.52% 4.89%
Supreme Cannabis N/A N/A N/A
: In the previous week, Medexus Pharmaceuticals had 1 more articles in the media than Supreme Cannabis. MarketBeat recorded 1 mentions for Medexus Pharmaceuticals and 0 mentions for Supreme Cannabis. Medexus Pharmaceuticals' average media sentiment score of 0.00 equaled Supreme Cannabis'average media sentiment score.
Company Overall Sentiment
Medexus Pharmaceuticals Neutral
Supreme Cannabis Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$99.43M	1.27	C$3.26M	-C$0.02	N/A
Supreme Cannabis	C$53.29M	0.00	-C$23.65M	-C$0.03	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Supreme Cannabis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	-0.27%	-0.52%	4.89%
Supreme Cannabis	N/A	N/A	N/A

Company	Overall Sentiment
Medexus Pharmaceuticals	Neutral
Supreme Cannabis	Neutral

Summary

Medexus Pharmaceuticals beats Supreme Cannabis on 9 of the 13 factors compared between the two stocks.

Get Medexus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDP vs. The Competition

Export

Metric	Medexus Pharmaceuticals	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$125.97M	C$1.62B	C$6.25B	C$11.72B
Dividend Yield	N/A	2.97%	2.74%	6.22%
P/E Ratio	-195.00	4.18	24.91	23.83
Price / Sales	1.27	1,488.53	504.56	13.46
Price / Cash	N/A	10.37	43.30	82.69
Price / Book	2.42	10.72	9.67	4.48
Net Income	C$3.26M	C$21.15B	C$3.55B	C$300.68M
7 Day Performance	-1.27%	-1.16%	1.70%	0.12%
1 Month Performance	11.43%	0.17%	5.62%	2.88%
1 Year Performance	43.91%	24.19%	34.42%	57.78%

Medexus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDP Medexus Pharmaceuticals	0.0007 of 5 stars	C$3.90 +0.5%	N/A	N/A	C$125.97M	C$99.43M	N/A	98	News Coverage Gap Up
CPH Cipher Pharmaceuticals	N/A	C$17.60 -2.8%	N/A	N/A	C$444.95M	C$50.45M	16.76	5	Gap Up
SUGR SugarBud Craft Growers	N/A	C$11.47 flat	N/A	N/A	C$276.07M	C$668.94M	6.83	44	Gap Up High Trading Volume
ACB Aurora Cannabis	2.0225 of 5 stars	C$4.66 +3.3%	C$9.25 +98.5%	N/A	C$275.53M	C$373.12M	N/A	1,073	Positive News
OGI Organigram	3.5773 of 5 stars	C$1.91 +2.7%	C$3.13 +63.6%	N/A	C$268.62M	C$279.99M	12.40	987

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:MDP) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medexus Pharmaceuticals (MDP) Competitors

MDP vs. CPH, SUGR, ACB, OGI, and FIRE

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Summary

How does Medexus Pharmaceuticals compare to SugarBud Craft Growers?

Summary

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Summary

How does Medexus Pharmaceuticals compare to Organigram?

Summary

How does Medexus Pharmaceuticals compare to Supreme Cannabis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDP vs. The Competition

Medexus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medexus Pharmaceuticals (MDP) Competitors

MDP vs. CPH, SUGR, ACB, OGI, and FIRE

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Summary

How does Medexus Pharmaceuticals compare to SugarBud Craft Growers?

Summary

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Summary

How does Medexus Pharmaceuticals compare to Organigram?

Summary

How does Medexus Pharmaceuticals compare to Supreme Cannabis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDP vs. The Competition

Medexus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools